The U.S. Food and Drug Administration (FDA) approved Givosiran on November 20, 2019, for the treatment of acute hepatic porphyria (AHP) in adults.

The U.S. Food and Drug Administration (FDA) approved Crizanlizumab on November 15, 2019.

The U.S. Food and Drug Administration (FDA) approved Zanubrutinib on November 14, 2019.

The U.S. Food and Drug Administration (FDA) approved Cefiderocol on November 14, 2019, for the treatment of complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP).

The U.S. Food and Drug Administration (FDA) approved Reblozyl on November 8, 2019, for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

The U.S. Food and Drug Administration (FDA) approved diroximel fumarate, marketed under the brand name Vumerity, on October 29, 2019.

Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, was approved by the U.S. Food and Drug Administration (FDA) on October 21, 2019.

The FDA granted approval for lasmiditan on October 11, 2019. This approval marked the introduction of lasmiditan as a novel treatment option for the acute management of migraine attacks in adults, with or without aura.

The FDA approved Beovu on October 7, 2019, for the treatment of neovascular (wet) age-related macular degeneration (AMD).

The FDA approved trifarotene on October 4, 2019, for the treatment of acne vulgaris. It is marketed under the brand name Aklief.

Tenapanor, marketed under the brand names Ibsrela and Xphozah, has been approved by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C) and for lowering phosphorus levels in the blood in adults with kidney disease.

The U.S. Food and Drug Administration (FDA) approved lefamulin on August 19, 2019, making it the first pleuromutilin antibiotic available for systemic administration in humans.